Call for Letters of Interest Research on innovative approaches for safety monitoring in Seasonal Malaria Chemoprevention Deadline for submission: 23 December 2014 ___________________________________________________________________________________ Research teams from African institutions are invited to submit Letters of Interest (LoI) for research on piloting innovative approaches for safety monitoring in the context of seasonal malaria chemoprevention. Under this call, one or two research teams are expected to be selected for funding for a maximum amount of US$ 75 000 each. Background and rationale WHO recommends for malaria prevention that children aged 3-59 months living in areas of highly seasonal malaria transmission in the Sahel sub-region receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) administered monthly for up to four months of the year during the period when the children are at greatest risk. Since the WHO recommendation for SMC was issued in March 2012, countries have included SMC in their strategic plans for malaria control, and several have started to implement it on the field. As with all such programmes, adequate safety monitoring should be ensured where SMC is introduced. However, in many countries where SMC will be implemented, there is currently no robust system for collecting in an efficient and reliable manner information on safety in such mass treatment interventions. Implementation research is therefore needed to determine effective and sustainable methods for monitoring the safety of SMC, as part of a broader system of pharmacovigilance in health programmes. This call fits within TDR’s focus to help low- and middle-income countries develop innovative tools and strategies targeting neglected tropical disease. υ Objectives The overall objective of the call is to support one or two African research teams to pilot innovative approaches for safety monitoring in the context of seasonal malaria chemoprevention. The specific objectives are, primarily, to test new methodologies or practices aiming at strengthening safety monitoring, and secondarily, to generate data on the safety of SP+AQ used in the context of SMC. The expected outcome is data that would aid evidence-based decisions for recommendations on methodologies to be implemented for safety monitoring in SMC, and potentially in other preventive mass drug administration programmes. Methodologies The research proposal should focus on new and innovative approaches to improve the quality and effectiveness of safety monitoring systems in the context of SMC. The project is to be embedded in the normal SMC activities implemented by the national malaria control programme, and should ideally be carried out in collaboration with the national pharmacovigilance centre. Examples of interventions and research questions within the scope of this call: (This list is for guidance on the scope of projects we expect to see. It is not exhaustive. Proposals addressing questions relevant to the call specifications but not stated below are welcome.) o o o o o o Developing innovative approaches for safety monitoring; Setting up active methodology for safety monitoring of adverse events; Empowering community health workers to report safety information collected at community level; Demonstrating activities or elements that will strengthen effectiveness of current pharmacovigilance systems; Demonstrating how can mobile technology (such as mobile phone) contribute to improved pharmacovigilance in the context of SMC; Demonstrating how regional networking can support safety monitoring of SMC. Funding scope Funds may be requested to support direct costs attributable to the study, including research staff time (excluding the principal investigator), direct costs due to specific follow-up, consumables and equipment. The funding is available for research only. TDR will not fund treatment and routine delivery of health services needed for the organization and delivery of the SMC or the treatments of adverse events. Applicants should build the safety monitoring project within the implementation of SMC at country level and identify at the application stage the health facilities and referral structures which will provide any health service delivery relevant to the project, including medical management of adverse events and adverse drug reactions. The successful project will be awarded funding for implementation during the 2015 SMC season. φ Selection process The candidates will be selected following an open competitive call for applications. The applications will be evaluated based on scientific merit, relevance to the call and feasibility. For those project(s) selected for funding, TDR will work with investigators to develop a protocol for implementation. Final protocols will need to be approved by the WHO Ethics Review Committee and relevant local research ethics committees before funds can be made available and projects can start implementation. Eligibility criteria • Resources secured to ensure a functional seasonal malaria chemoprevention programme during 2015 and willingness of the partners involved in SMC delivery to participate in the implementation of the research on safety monitoring; • Referral system in place for management of adverse events and adverse drug reactions; • Principal Investigators must be based in the country where the project will take place; • Proposed project is planned to be implemented in 2015. Evaluation criteria Upon verification of eligibility by TDR staff, applications will be reviewed and evaluated by an external scientific working group in consideration of the following criteria: Relevance to the call • • • • How much the proposed research falls within the scope of the call Innovation potential Potential impact Linkage with the national pharmacovigilance centre Feasibility • • • • • • Coherence and effectiveness of the work plan Potential to be implemented smoothly with the identified resources Quality/suitability of the institution(s)/team (composition, expertise) for the proposed tasks Feasible implementation timelines Budget and funding Risks identified and mitigation measures Scientific merit • Investigator and team knowledge, expertise and experience Application Applications should be submitted online. A 7-10 page letter of interest should provide a brief outline of the technical and operational feasibility for the proposed project (see below). A one-page summary CV of the principal investigator and a supporting letter from the institution’s director should also be attached. χ The following content should be included in the letter of interest to provide evidence on the feasibility of the project at your site: o o o o o o o o Brief description of institution’s mandate, structure, staff, current activities, research experience (maximum 1 page). Brief description (maximum 1 page) of the SMC implementation plans for SMC season 2015 including areas and number of children to be targeted, number of rounds and months targeted, strategy for SMC delivery, actors to be involved in the SMC implementation and foreseen contribution of each actor (please include also actors or partners responsible of SMC implementation on the field, drug provision). Confirmation of the funding and drug supply secured for the implementation in 2015 should be included. Brief description of the current safety reporting system and tools in the country (maximum 1 page). Description of the proposed research project (minimum 3 pages – maximum 6 pages), including the methodology proposed, target area for the project implementation, partners to be involved if any, number of children to be targeted by the safety monitoring intervention proposed. Staffing proposed for the study including number of field workers / community health workers. Proposed budget breakdown. Proposed timelines (please include foreseen timing for ethical submission if applicable). Foreseeable risks to the successful achievement of project objectives, along with proposed measures to mitigate those risks. Applications can be submitted in English or French. All applications must be completed and submitted online using the WHO DataCol portal form found on this link: https://extranet.who.int/datacol/survey.asp?survey_id=3152 The log-in credentials are: User name: callPVSMC - Password: iir-tdr Only applications submitted through this online portal will be considered for review. Deadline for submission of letters of interest: 23 December 2014, 16.00 GMT. Additional application information: • • • An active email address is required to use this portal. A confirmation email will be sent to this address to acknowledge successful submission. Only one application may be submitted by each team or individual. Multiple submissions will not be processed. Information and documents to be uploaded are stated in the online application form. Applicants are advised to prepare the supporting documentation prior to starting the submission process. Applicants are encouraged to familiarize themselves with the DataCol application form, in particular the requested information and documents, paying particular attention to the mandatory fields marked with an asterisk (*). Applicants are advised to avoid last minute submissions as this could overload the system or fail due to internet connectivity problems. Applications received after the deadline will not be considered. ψ • Please contact TDR ([email protected]) if you encounter technical difficulties during the completion and submission of the application form. Please mention “Call PV SMC” in the subject of your message. For further information on the call, please contact: Dr Christine Halleux Special Programme for Research and Training in Tropical Diseases (TDR) World Health Organization 1211 Geneva 27, Switzerland Telephone: +41 22 791 2559 E-mail: [email protected] ω
© Copyright 2024